In Other News

• Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease

• FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors

• Simple Cytogenetic Method Could Improve Classification of ALL Subtypes

• Diazyme Laboratories Acquires Carolina Liquid Chemistries

• Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia

• Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response

• Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean

• Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection

• Multi-Cancer Test Boosts Detection When Added to Standard Screening

• Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia

• Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer

• Study Points to Autoimmune Pathway Behind Long COVID Symptoms

• AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines

• Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand

• Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis

• Global Framework Integrates Digital Pathology for Companion Diagnostic Development

• GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026

• Agentic AI Platform Supports Genomic Decision-Making in Oncology

• MCED Blood Test Reduces Stage IV Cancer Diagnoses in NHS Trial

• Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

• Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows

• AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes

• Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity